{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:10:12Z","timestamp":1744431012014,"version":"3.40.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"DOI":"10.7759\/cureus.82076","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:47:01Z","timestamp":1744372021000},"source":"Crossref","is-referenced-by-count":0,"title":["Malignant Melanoma of the Foot in Five Elderly Patients: Clinicopathologic Features and Treatment Outcomes"],"prefix":"10.7759","author":[{"given":"Jekin J","family":"Sharon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokulesh","family":"D G","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalraj","family":"M","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Vital signs: melanoma incidence and mortality trends and projections \u2014 United States, 1982-2030","volume":"64","author":"Guy GP Jr","year":"2015","unstructured":"Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: melanoma incidence and mortality trends and projections \u2014 United States, 1982-2030. MMWR Morb Mortal Wkly Rep. 2015, 64:591-6.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328335a8dd","article-title":"Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment","volume":"20","author":"Lasithiotakis KG","year":"2010","unstructured":"Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res. 2010, 20:163-70. 10.1097\/CMR.0b013e328335a8dd","journal-title":"Melanoma Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4287","article-title":"Cutaneous melanoma: from pathogenesis to therapy (review)","volume":"52","author":"Leonardi GC","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R, et al.. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol. 2018, 52:1071-80. 10.3892\/ijo.2018.4287","journal-title":"Int J Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald JE","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al.. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017, 67:472-92. 10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter SM","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al.. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019, 80:208-50. 10.1016\/j.jaad.2018.08.055","journal-title":"J Am Acad Dermatol"},{"key":"ref6","article-title":"WHO Classification of Skin Tumours","year":"2018","unstructured":"WHO Classification of Skin Tumours. Elder DE, Massi D, Scolyer RA, Willemze R (ed). World Health Organization, Geneva, Switzerland; 2018."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber J","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al.. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017, 377:1824-35. 10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit DG","year":"2016","unstructured":"Coit DG, Thompson JA, Algazi A, et al.. Melanoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016, 14:450-73. 10.6004\/jnccn.2016.0051","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.jfas.2017.07.018","article-title":"Melanoma of the foot is associated with advanced disease and poorer survival","volume":"57","author":"Adams BE","year":"2018","unstructured":"Adams BE, Peng PD, Williams ML. Melanoma of the foot is associated with advanced disease and poorer survival. J Foot Ankle Surg. 2018, 57:52-5. 10.1053\/j.jfas.2017.07.018","journal-title":"J Foot Ankle Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-23. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf D","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, et al.. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015, 33:1889-94. 10.1200\/JCO.2014.56.2736","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries MB","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al.. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017, 376:2211-22. 10.1056\/NEJMoa1613210","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016","volume":"63","author":"Garbe C","year":"2016","unstructured":"Garbe C, Peris K, Hauschild A, et al.. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer. 2016, 63:201-17. 10.1016\/j.ejca.2016.05.005","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont AM","year":"2018","unstructured":"Eggermont AM, Blank CU, Mandala M, et al.. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018, 378:1789-801. 10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/345868-malignant-melanoma-of-the-foot-in-five-elderly-patients-clinicopathologic-features-and-treatment-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:47:02Z","timestamp":1744372022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/345868-malignant-melanoma-of-the-foot-in-five-elderly-patients-clinicopathologic-features-and-treatment-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.82076","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}